A Phase 3, Multicenter, Open-Label, 12-Month Extension Safety and Tolerability Trial of Lisdexamfetamine Dimesylate in Adults With Binge Eating Disorder
2017 ◽
Vol 37
(3)
◽
pp. 315-322
◽
Keyword(s):
Phase 3
◽